DYN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DY

Mkt Cap

$2.66B

Volume

2.36M

Next Earnings

November 4th

Loading chart

DY

DYNDyne Therapeutics, Inc. Common Stock

DYN

Pay with—

Available Balance0.00

DY

Mkt Cap

$2.86B

Volume

2.36M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common StockDyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, generating gross proceeds of approximately $375.2 million. The offering is expected to close on July 23, 2026, with underwriters granted a 30-day option to purchase an additional 2.745 million shares. Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers.GlobeNewswire Inc. · Jul 22, 2026

Dyne Therapeutics Announces Proposed Public Offering of Common StockDyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.GlobeNewswire Inc. · Jul 21, 2026

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.The Motley Fool · Jun 26, 2026

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could MeanFCPM III Services B.V. reduced its Dyne Therapeutics position by 818,460 shares ($14.11 million) in May 2026, though the fund maintains Dyne as its second-largest holding at 11.8% of assets. Despite the partial exit, the stake reduction appears strategic rather than a loss of conviction, as Dyne shares have surged 56% over the past year. The company recently submitted a Biologics License Application for its lead Duchenne muscular dystrophy therapy z-rostudirsen, targeting potential FDA approval and U.S. launch in Q1 2027.The Motley Fool · May 30, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.GlobeNewswire Inc. · May 26, 2026

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of SharesSaturn V Capital Management sold 822,007 shares of Dyne Therapeutics (worth $14.17 million) in Q1 2026, despite the stock being up 40% over the past year. The fund retained nearly 1 million shares, suggesting a trimming of exposure after the stock's sharp run. Dyne completed a positive pre-BLA meeting with the FDA for z-rostudirsen and remains on track for a biologics license application submission in Q2 2026, with a potential U.S. launch targeted for early 2027.The Motley Fool · May 19, 2026

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)Dyne Therapeutics has initiated the Phase 3 HARMONIA trial to evaluate z-basivarsen (DYNE-101) in approximately 150 patients with myotonic dystrophy type 1 (DM1). The 48-week randomized, placebo-controlled trial uses the five times sit to stand test as its primary endpoint and is designed to support conversion of Accelerated Approval to traditional FDA approval and ex-U.S. marketing applications.GlobeNewswire Inc. · Mar 8, 2026

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific ConferenceDyne Therapeutics will present five presentations at the 2026 MDA Clinical & Scientific Conference, including new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD and Phase 3 trial design for z-basivarsen in DM1. The presentations demonstrate the strength of Dyne's FORCE platform across three neuromuscular diseases.GlobeNewswire Inc. · Feb 22, 2026

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common StockDyne Therapeutics plans to raise $350 million through a public offering of 18,980,478 common stock shares at $18.44 per share, with potential additional shares through underwriter option.GlobeNewswire Inc. · Dec 10, 2025

Biggest Market Movers Today, Dec. 9: WRBY, DYN, & MoreStock markets remained relatively stable on Tuesday, awaiting the Federal Reserve's interest rate decision. Notable movements included gains for Warby Parker on AI prospects and Pan American Silver due to rising silver prices, while Dyne Therapeutics and SLM experienced stock price declines.The Motley Fool · Dec 9, 2025

to start trading

DY

DYNDyne Therapeutics, Inc. Common Stock

DYN

Pay with—

Available Balance0.00

Your PositionYou don't own any DYN yet.

Related Tickers

Earnings